Latest News
Pulse Biosciences, Inc.
- Pulse Biosciences, Inc. Estimates – HAM:6L8
- Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026
- Total cash dividends paid of Pulse Biosciences, Inc. – FWB:6L8
- Pulse Biosciences, Inc. Balance Sheet – XETR:6L8
- Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
- Pulse Biosciences (PLSE) Could Be 7% Undervalued On NANOPULSE AF Enrollment Milestone
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
- Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation Treatment
- Pulse Biosciences hits 164-patient enrollment target in NANOPULSE-AF pivotal IDE study
- Pulse Biosciences: Promising Technology, But Hard To Justify Its Valuation (NASDAQ:PLSE)
- Pulse Biosciences stock reports 100 patient trial milestone
Headlines from the last 30 days, linking to the original publishers. See all market news →